36
The
th Annual Meeting of March 21-22, 2015 The Endocrine Society and The Diabetes Association of the R.O.C. (Taiwan)
SD-2-1
Journey to Individualized Insulin Therapy: From Clinical Trial to Real World Experience Stephen L. Atkin Medical Department, Weill Cornell Medical College in Qatar (WCMC-Q)
Diabetes is a chronic disease requiring ongoing medical care and well patient self-management. In addition to lifestyle modification, oral hypoglycemic agents, and glucagon-like peptide-1 receptor agonist -based therapy, exogenous insulin injection is essential in type 1 diabetes and becomes vital in patients with long-term type 2 diabetes who could not achieve optimal glycemic control. One of the risks that concerns insulin treatment most is hypoglycemia. Therefore, optimal insulin regimen should reduce the risk of hypoglycemia while improving glycemic control. As the disease progress, basal insulin initiation provides a remarkable benchmark, and rapid-acting prandial insulin doses can easily be added when optimization is needed. From certain perspectives of simplicity and convenience, premix insulin regimens could be another effective option for insulin intensification therapy. In addition to achieve glycemic control as one of the diabetes management goal, weight management and hypoglycemia risk should also be considered. Personalized diabetes treatment goal is recommended to both physicians and patients.
108
